Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
LOS ANGELES, April 27, 2017 -- Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NYSE:TXMD) concerning possible violations of federal securities laws between July 7, 2016 and April 9, 2017 inclusive (the “Class Period”). Investors who purchased or otherwise acquired the Company’s shares during the Class Period should contact the firm prior to the June 19, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, throughout the Class Period, TherapeuticsMD made false and/or misleading statements and/or failed to disclose that the Company’s New Drug Application (“NDA”) submission for TX-004HR was deficient and was not supported by the complete TX-004HR clinical program, which would likely cause a delay of the Food & Drug Administration’s potential approval of the NDA. When this information was released, the Company’s stock price decreased materially, which harmed investors according to the Complaint.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/
